Abstracts Archive - Page 1587 of 2425 - ACR Meeting Abstracts

Abstract Number: 2549 • 2016 ACR/ARHP Annual Meeting
Effect of Interleukin-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type 9 Serum Levels in Rheumatoid Arthritis Patients
Maria Vanesa Hernandez-Hernandez¹, Esmeralda Delgado-Frias², Beatriz Tejera³, Cristina Luna Gomez⁴, Jose Ramon Muñiz^5,6, De Vera-González AM⁷, Sagrario Bustabad⁸, Ivan Ferraz-Amaro⁸ and Federico Díaz-González⁹, ¹Rheumatology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ²Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain, ³Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁴Rosario S/N, H. Ntra. Sra. La Candelaria, Santa Cruz de Teneri, Spain, ⁵Radiology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ⁶Radiology, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁷Central Laboratory Division, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁹Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain
Background/Purpose: Rheumatoid arthritis (RA) has been acknowledged to increase cardiovascular mortality probably due, in part, to a lipid profile different from that observed in the…
Abstract Number: 2550 • 2016 ACR/ARHP Annual Meeting
Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients
Joern Kekow¹ and Susanne Drynda², ¹University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ²University of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany
Background/Purpose: The application of biologic substances is subject to a risk to develop antibodies against these structures causing adverse events or loss of efficacy. For…
Abstract Number: 2551 • 2016 ACR/ARHP Annual Meeting
Impact of Multmorbidity on Disability and Disease Activity over Time in Patients with RA Taking Biologics: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Jennifer Humphreys¹, Kath Watson², Mark Lunt^2,3, Deborah P.M. Symmons^2,4,5, Kimme L. Hyrich^2,4,6 and the BSRBR-RA, ¹Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Multimorbidity is increasingly prevalent in western populations and has the potential to influence disease specific outcomes. Rheumatoid arthritis (RA) is a chronic inflammatory…
Abstract Number: 2552 • 2016 ACR/ARHP Annual Meeting
Predictive Value of Chest HRCT Patterns for Respiratory Adverse Event Among RA Patients Treated with Biological Therapy: Long-Term Results from an Observational Study
Takuya Matsumoto¹, Toshihisa Kojima¹, Nobunori Takahashi¹, Shuji Asai¹, Nobuyuki Asai¹, Tatsuo Watanabe², Tomonori Kobayakawa³, Naoki Ishiguro⁴, Shingo Iwano⁵ and Satoru Ito⁶, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Orthopeadic Sugery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ⁵Department of Radiology, Nagoya University Hospital, Nagoya, Japan, ⁶Department of Respiratory Medicine, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Biological therapy brought an important advance in the treatment strategy for rheumatoid arthritis (RA). However, the safety of biological therapy on RA patients with…
Abstract Number: 2553 • 2016 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database
H Yu, K Angelini, A Dominique and TA Simon, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Women are affected by RA 3–4 times more often than men. RA treatment choice during pregnancy can be a challenge for women to minimize…
Abstract Number: 2554 • 2016 ACR/ARHP Annual Meeting
Changes in Blood Pressure Following the Initiation of Disease Modifying Therapies in US Veterans with Rheumatoid Arthritis
Joshua Baker¹, Brian Sauer², Chia-Chen Teng³, Grant W. Cannon⁴, Said Ibrahim⁵, Michael George⁶, Amy C. Cannella⁷, Bryant R. England⁸, Liron Caplan⁹, Lisa A. Davis¹⁰, Kaleb Michaud¹¹, James R. O'Dell¹² and Ted R Mikuls¹³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT, ⁵Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁷Section of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ¹⁰Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ¹¹University of Nebraska Medical Center, Omaha, NE, ¹²Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹³Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Chronic inflammation is associated with a greater risk of hypertension (HTN) while inflammatory cytokines such as TNF-α have been shown to have vasodilator effects.…
Abstract Number: 2555 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Katerina Chatzidionysiou¹, Sharzad Emamikia², Jackie L. Nam³, Sofia Ramiro⁴, Josef Smolen⁵, Désirée van der Heijde⁶, Maxime Dougados⁷, Johannes WJ Bijlsma⁸, Gerd Burmester⁹, Marieke Scholte-Voshaar¹⁰, Ronald van Vollenhoven^11,12 and Robert Landewé¹³, ¹Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Paris Descartes University, Paris, France, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité University Hospital, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ¹³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy…
Abstract Number: 2556 • 2016 ACR/ARHP Annual Meeting
Deficient Expression of the Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Induces S Phase Arrest in RA Fibroblast-like Synoviocytes (FLS)
Shinji Matsuda¹, Deepa Hammaker², Steven Dowdy³, David L. Boyle⁴ and Gary Firestein⁵, ¹Medicine, UC San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³UC San Diego School of Medicine, La Jolla, CA, ⁴Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁵Medicine, UCSD, La Jolla, CA
Background/Purpose: LBH (Limb-bud and heart development) was recently identified as an RA risk gene that has abnormally methylated loci and a functional enhancer SNP in…
Abstract Number: 2557 • 2016 ACR/ARHP Annual Meeting
Tumor Necrosis Factor (TNF) Sensitizes Rheumatoid Synovial Fibroblasts to TRPA1-Mediated Calcium Flux, Anti-Proliferation and Cell Death
Torsten Lowin¹, Rainer Straub² and Georg Pongratz³, ¹Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany, ²Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, ³Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) are one main contributor of joint destruction since they resist apoptosis and secrete pro-inflammatory cytokines and matrix…
Abstract Number: 2558 • 2016 ACR/ARHP Annual Meeting
Dissociation of the Inhibitory Apoptosis Stimulating Protein of p53 (iASPP) Binding with Transcription Factor p73 Induces Synovial Fibroblast Apoptosis in the Rheumatoid Joint
Chrong-Reen Wang¹, Shih-Yao Chen¹, Ai-Li Shiau², Ming-Fei Liu¹ and Chao-Liang Wu³, ¹Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan, ²Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose: Apoptosis-resistant synovial fibroblasts (SFs) constitute the major cell component of pannus tissues in rheumatoid arthritis (RA). In tumor cells, the binding of inhibitory…
Abstract Number: 2559 • 2016 ACR/ARHP Annual Meeting
Subgingival Microbiome Signatures in Patients with Established Rheumatoid Arthritis and Osteoarthritis
Ted R Mikuls¹, Clay Walker², Fang Qiu³, Fang Yu⁴, Geoffrey M. Thiele⁵ and Jeffrey Payne⁶, ¹Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²College of Dentistry, University of Florida, Gainesville, FL, ³Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁴Public Health, University of Nebraska Medical Center, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶College of Dentistry, University of Nebraska Medical Center, Lincoln, NE
Background/Purpose: Periodontitis (PD) is an inflammatory disease of tissues supporting the teeth, caused by microorganisms that adhere to and grow along the tooth’s surface. …
Abstract Number: 2560 • 2016 ACR/ARHP Annual Meeting
Sputum Antibody to Malondialdehyde-Acetaldehyde Adduct in Subjects with Established Rheumatoid Arthritis
Bryant R. England^1,2, Peter Maloley³, Eric Daubach³, Michael J. Duryee⁴, M. Kristen Demoruelle⁵, Kevin D. Deane⁵, Geoffrey M. Thiele⁶ and Ted R Mikuls⁶, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western Iowa, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Anti-malondialdehyde-acetaldehyde adduct (MAA) antibodies target immunogenic products of oxidative stress, are detected in higher concentration in paired synovial fluid vs serum in RA, and…
Abstract Number: 2561 • 2016 ACR/ARHP Annual Meeting
A Novel Pharmacological Action of MTX on RA Fibroblast-like Synoviocytes Via Circadian Clock Genes
Kohjin Suzuki¹, Kohsuke Yoshida¹, Teppei Hashimoto², Kenta Kaneshiro¹, Ayako Nakai¹, Naonori Hashimoto¹, Yoshiko Kawasaki², Nao Shibanuma³, Natsuko Nakagawa⁴, Yoshitada Sakai⁵ and Akira Hashiramoto⁶, ¹Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, ³Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁴Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, ⁵Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Biophysics, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: The circadian rhythm is disrupted in patients with rheumatoid arthritis (RA), and we have shown that tumor necrosis factor(TNF)-ƒ¿ inhibits the expression of circadian…
Abstract Number: 2562 • 2016 ACR/ARHP Annual Meeting
Human Seroreactivity to Gut Microbiota Antigens in Rheumatoid Arthritis and Controls-Lack of Association with Rheumatoid Arthritis Autoantibodies
Carol Hitchon¹, Charles O. Elson², David Robinson³, Irene Smolik³ and Hani S. El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Dept of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The human gut microbiome maintains normal immune homeostasis. Changes to the microbiota evolve with aging and have been implicated in the development of autoimmune…
Abstract Number: 2563 • 2016 ACR/ARHP Annual Meeting
Hypoxia Induce Slug Expression Via JAK/STAT3 Pathway in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Hyungjin Kim¹, Hyemin Jeong², Jaejoon Lee², Hoon-Suk Cha¹, Eun-Mi Koh³, Eun-Jung Park⁴ and Young Hee Eun¹, ¹Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Medicine, Division of Rheumatology, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea
Background/Purpose: Accumulating evidence implicates hypoxia in the pathogenesis of rheumatoid arthritis (RA). The effect of hypoxia on the expression of Slug, a transcriptional repressor that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].